Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich to Provide CRISPR Technology to UMich Medical School

NEW YORK (GenomeWeb) – Sigma-Aldrich today announced a gene editing partnership to provide the University of Michigan Medical School's Vector Core with its CRISPR technology, experimental design consultation, and dedicated gene editing bioinformaticians.

According to Sigma-Aldrich, the partnership will accelerate research directed at gene editing at the medical school, which has one initiative underway to construct a large library of Sigma CRISPRs for precision studies of the 100 most common genes that have dysfunctions associated with cancer. The research is led by Assistant Professor Chad Brenner and is expected to support the creation of a dataset of oncogene functions and drug resistance that could be used to improve decision making for the treatment of cancer.

Using the CRISPR-Cas9 technology, Brenner and his fellow researchers will be able "to define the genes and pathways that drive resistance to existing cancer therapies to aid in the development of more effective combination strategies for patients," Brenner said in a statement.

Today's deal will provide other researchers throughout the UM Medical School the same access to extensive experimental design, bioinformatics, and production resources that Brenner already receives from Sigma-Aldrich, the company said.

"The Sigma-Aldrich CRISPR Core partnership helps accelerate the pace of translational research, removing the design and production hurdles with CRISPR or zinc finger nucleases, hence allowing scientists to focus on their research," Sigma-Aldrich Director of Strategic Marketing and Collaborations Sean Muthian said.

Financial and other terms of the agreement were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.